In the NZ Herald Business Section today.
'' A failed Australian biotechnology developer's cervical cancer screening technology has been resurrected by an Auckland company that will list on the New Zealand sharemarket this week."
Martin Dillon is the Chief Executive, was Polartechnics general manager for sales.
Robert Hunter is going to Chair the new company.
Truscreen is listing on the NZAX this week.
Dillon said $400k in export revenue was generated in the first 6 months of current financial year.
Truscreen is forecasting a $2.2m profit on sales of over $10m in the 2016 year.
...........................................
You can find the article in today's business section of the NZ Herald page B 18
To think of what might have been if the wheel hadn't fallen of?
Regards
Dabru
DYOR
PLT Price at posting:
7.1¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)